Which of the following could be a potential therapeutic target for diseases involving dysfunctional RTK pathways?

• A. Drugs that enhance ligand binding to RTKs.
• B. Inhibitors that block RTK dimerization.
• C. Compounds that degrade SH2 domain-containing proteins.
• D. Agents that increase RTK autophosphorylation.

Answer: (B)